•  
  •  
 

Abstract

Currently, coronavirus disease 2019 (COVID-19) is a very serious health problem. The World Health Organization (WHO) has characterized this disease as a pandemic. Recommendations related to vaccines and drugs are not available yet because they are still in the clinical trial phase, and one of the superior drugs is remdesivir which has an antiviral activity. Several clinical trials of this drug are being carried out with the aim of evaluating its safety and efficacy in COVID-19 patients. There are two clinical trials with completed recruitment status, which are NCT04257656 and NCT04280705. NCT04257656 showed that remdesivir had faster time for clinical improvement in severe COVID-19 patients compared to placebo although it was not found to be statistically significant. Moreover, NCT04280705 showed that remdesivir was superior compared to placebo in shortening the recovery time in hospitalized adults with COVID-19. Gilead Sciences is also conducting clinical trials on this drug, and WHO has also conducted a solidarity trial and INSERM DisCoVery trials on remdesivir. Based on two clinical trials completed, satisfactory results are shown in patients with remdesivir therapy compared with patients who received placebo, although it is very important to wait for the results of other ongoing clinical trials to strengthen the evidence of the safety and efficacy of this drug.

References

Ahmad, A., Rehman, M. U., Alkharfy, K. M. (2020). An alternative approach to minimize the risk of coronavirus (COVID-19) and similar infections. European Review for Medical and Pharmacological Sciences, 24(7), 4030- 4034.

Ahsan, W., Javed, S., Bratty, M.A., Alhazmi, H.A., & Najmi, A. (2020). Treatment of SARS-CoV-2: How far have we reached?. Drug Discoveries & Therapeutics, 14(2), 67-72.

Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., Smith, E.C., Case, J.B., Feng, J.Y., Jordan, R., Ray, A.S., Cihlar, T., Siegel, D., Mackman, R.L.,Clarke,M.O.,Baric,R.S.,&Denison,M.R.(2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9(2), 1-15.

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A.K. (2020). Remdesivir for the treatment of COVID-19 - Preliminary report. The New England Journal of Medicine, doi: 10.1056/NEJMoa2007764.

Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., Ciccozzi, M. (2020). The 2019-new coronavirus epidemic: Evidence for virus evolution. Journal of Medical Virology, 92(4), 455–459.

Branswell, H. (2020). WHO to launch multinational trial to jumpstart search for coronavirus drugs (World Health Organization). Available at: http://www.statnews. com/2020/03/18/who-to-launch-multinational-trial-to- jumpstartsearch-for-coronavirus-drugs/. Accessed on 15 July 2020.

Cao, Y. C., Deng, Q. X., Dai, S. X. (2020). Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease, 35, 101647.

Cao, B. (2020a). Mild/Moderate 2019-nCoV Remdesivir RCT. Available at: https://clinicaltrials.gov/ct2/show/ NCT04252664. Accessed on 15 July 2020.

Cao, B. (2020b). Severe 2019-nCoV Remdesivir RCT. Available at: http://clinicaltrials.gov/ct2/show/ NCT04257656. Accessed on 15 July 2020.

Coppock, K. (2020). FDA announces two drugs approved for ‘Compassionate Use’ in treating COVID-19. (Pharmacy Times). Available at: https://www. pharmacytimes.com/news/fda-announces-two-drugs- approved-forcompassionate-use-in-treating-covid-19. Accessed on 15 July 2020.

Dornemann, J., Burzio, C., Ronsse, A., Sprecher, A., Clerck, H.D., Herp, M.V., Kolie, M.C., Yosifiva, V., Caluwaerts, S., McElroy, A.K., & Antierens, A. (2017). First newborn baby to receive experimental therapies survives ebola virus disease. The Journal of Infectious Diseases, 215(2), 171-174.

Gilead Sciences. (2020a). Gilead sciences update on the company’s ongoing response to COVID-19. (GILEAD). Available at: https://www.gilead.com/purpose/ advancing-global-health/covid-19. Accessed on 15 July 2020.

Gilead Sciences. (2020b). Study to evaluate the safety and antiviral activity of remdesivir (GS-5734TM) in participants with severe coronavirus disease (COVID-19). Available at: https://clinicaltrials.gov/ct2/ show/NCT04292899. Accessed on 15 July 2020.

Gilead Sciences. (2020c). Study to evaluate the safety and antiviral activity of remdesivir (GS-5734TM) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. Available at: https://clinicaltrials.gov/ct2/show/ NCT04292730. Accessed on 15 July 2020.

Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., Gotte, M. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from middle east respiratory syndrome coronavirus. The Journal of Biological Chemistry, 295(15), 4773-4779.

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., et al. (2020). Compassionate use of remdesivir for patients with severe COVID-19. The New England Journal of Medicine, 382, 2327-36.

Holshue, M.L., De, B.C., Lindquist, S., Lofy, K.H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L., Patel, A., Gerber, SI., Kim, L., Tong, S., Lu, X., Lindstrom, S., Pallansch, M.A., Weldon, W.C., Biggs, H.M., Uyeki, T.M., & Pillai, S.K. (2020). First case of 2019 novel coronavirus in the United States. The New England Journal of Medicine, 382, 929-936.

INSERM. (2020). Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy). Available at: https:// clinicaltrials.gov/ct2/show/NCT04315948. Accessed on 15 July 2020.

Jacobs, M., Rodger, A., Bell, D.J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R.J., Hopkins, S., Hughes, J., Jabeen, F., Johannessen, I., Karageorgopoulos, D., Lackenby, A., Lester, R., Liu, RSN., MacConnachie, A., Mahungu, T., Martin, D., Marshall, N., Mepham, S., Orton, R., Palmarini, M., Patel, M., Perry, C., Peters, SE., Porter, D., Ritchie, D., Ritchie, N.D., Seaton, R.A., Sreenu, V.B., Templeton, K., Warren, S., Wilkie, G.S., Zambon, M., Gopal, R., & Thomson, E.C. (2016). Late ebola virus relapse causing meningoencephalitis: A case report. The Lancet, 388(10043), 498-503.

Kakodkar, P., Kaka, N., Baig, M. N. (2020). A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus, 12(4), 1-18.

Li, Z., Wang, X., Cao, D., Sun, R., Li, C., & Li, G. (2020). Rapid review for the anti-coronavirus effect of remdesivir. Drug Discoveries & Therapeutics, 14(2), 73- 76.

Lo, M.K., Friederike, F., Gary, J.M., Jordan, R., Bannister, R., Cronin, J., Patel, N.R., Klena, J.D., Nichol, S.T., Cihlar, T., Zaki, S.R., Feldmann, H., Spiropoulou, C.F., & Wit, E.D. (2019). Remdesivir (GS-5734) protects African green monkeys from nipah virus challenge. Science Translational Medicine, 11, 1-7.

McCreary, E. K., Pogue, J. M. (2020). Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases, 7(4), 1-11.

Mulangu, S., Dodd, L.E., Davey, R.T., Mbaya, O.T., Proschan, M., Mukadi, D., Manzo, M.L., Nzolo, D., Oloma, A.T., Ibanda, A., Ali, R., Coulibaly, S., Levine, A.C., Grais, R., Diaz, J., Lane, H.C., Tamfum, J.J.M., & PALM Writing Group, for the PALM Consortium Study Team. (2019). A randomized, controlled trial of ebola virus disease therapeutics. The New England Journal of Medicine, 381(24), 2293–2303.

NIAID. (2020). Adaptive COVID-19 Treatment Trial. Available at: https://clinicaltrials.gov/ct2/show/ NCT04280705. Accessed on 15 July 2020.

Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., Leist, S.R., Pyrc, K., Feng, J.Y., Trantcheva, I., Bannister, R., Park, Y., Babusis, D., Clarke, M.O., Mackman, R.L., Spahn, J.E., Palmiotti, C.A., Siegel, D., Ray, A.S., Cihlar, T., Jordan, R., Denison, M.R., & Baric, R.S. (2017). Broad- spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine, 9, 1-10.

Sheahan, T.P., Sims, A.C., Leist, S.R., Schafer, A., Won, J., Brown, A.J., Montgomery, S.A., Hogg, A., Babusis, D., Clarke, M.O., Spahn, J.E., Bauer, L., Sellers, S., Porter, D., Feng, J.Y., Cihlar, T., Jordan, R., Denison, MR., & Baric, R.S. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 11(1), 1-14.

Sisay, M. (2020). Available evidence and ongoing clinical trials of remdesivir: Could it be a promising therapeutic option for COVID-19. Frontiers in Pharmacology, 11, 791.

Song, W., Gui, M., Wang, X., Xiang, Y. (2018). Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLOS Pathogens, 14(8), 1-19.

US-AMRDC. (2020). Expanded Access Remdesivir (RDV; GS-5734TM). Available at: https://clinicaltrials. gov/ct2/show/NCT04302766. Accessed on 5 April 2020.

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271.

Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, FG., Horby, PW., Cao, B., & Wang, C. (2020). . Remdesivir in adults with severe COVID-19: A randomised, double- blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569-1578.

Warren, T., Jordan, R., Lo, M., Soloveva, V., Ray, A., Bannister, R., Mackman, R., Perron, M., Stray, K., Feng, J., Xu, Y., Wells, J., Stuthman, K., Welch, L., Doerffler, E., Zhang, L., Chun, K., Hui, H., Neville, S., Lew, W., Park, Y., Babusis, D., Strickley, R., Wong, P., Swaminathan, S., Lee, W., Mayers, D., Cihlar, T., & Bavari, S. (2015). Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola Virus Disease (EVD) in infected non-human primates. In Open Forum Infectious Diseases (Vol. 2, No. suppl_1, pp. LB-2). Infectious Diseases Society of America.

WHO. (2020). World Health Organization situation report. Available at: https://www.who.int/docs/default- source/coronaviruse/situation-reports/20200316-sitrep- 56-covid-19.pdf?sfvrsn=9fda7db2_2. Accessed on 20 March 2020.

Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., et al. (2020). Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses, 12(2), 244.

Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., & Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences, 63(3), 457- 460.

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., & Zhao, J. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine, 8(4), 420-422.

Yavuz, S. S., Unal, S. (2020). Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences, 50(SI- 1), 611-619.

Zhang, L., Zhou, R. (2020). Binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase. Preprints, 2020030267, doi: 10.20944/ preprints202003.0267.v1.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.